S11 Ep25: FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.

Visit the podcast's native language site